Abstract:Hyperhidrosis o`ccurs when the body produces sweat beyond what is essential to maintain thermal homeostasis. The condition tends to occur in areas marked by high-eccrine density such as the axillae, palms, and soles and less commonly in the craniofacial area. The current standard of care is topical aluminum chloride hexahydrate antiperspirant (10-20%), but other treatments such as anticholinergics, clonidine, propranolol, antiadrenergics, injections with attenuated botulinum toxin, microwave technology, and su… Show more
“…Two RCTs studied its use in hyperhidrosis, and results were equivocal but promising: one study on 19 patients noted improvement in hyperhidrosis on both the treated and untreated axilla, while another study on 100 patients noted it to be comparable to curettage. 26 There is a paucity of literature on utilization of diode laser in HS. Non-ablative light-based therapies in general have been shown to improve HS lesions.…”
Section: Discussionmentioning
confidence: 99%
“…The role of the diode laser in treatment of hyperhidrosis is not well studied. Two RCTs studied its use in hyperhidrosis, and results were equivocal but promising: one study on 19 patients noted improvement in hyperhidrosis on both the treated and untreated axilla, while another study on 100 patients noted it to be comparable to curettage 26 . There is a paucity of literature on utilization of diode laser in HS.…”
Hyperhidrosis impairs quality of life (QOL) in hidradenitis suppurativa (HS) patients and may exacerbate HS. However, there is limited literature on whether hyperhidrosis treatments improve HS disease. To systematically review literature on efficacy and tolerability of hyperhidrosis treatments in HS patients. In May 2021, MEDLINE and EMBASE databases were systematically searched by two reviewers per PRISMA guidelines for articles on hyperhidrosis and HS. Sixteen articles met inclusion criteria (2 randomized controlled trials [RCTs], one case-control study, three cross-sectional studies, 10 case-studies/ series), encompassing 252 HS patients across studies. They examined botulinum toxin A (BTX-A) (n = 6) and B (BTX-B) (n = 1), suction-curettage (n = 1), diode laser (n = 1), and microwave-based energy device (MED) (n = 3). Overall, BTX treatments improve HS severity, QOL, hyperhidrosis, and were well-tolerated. Suction-curettage did not improve disease. One HS patient tolerated diode laser well, with improvement in sweating and HS. One RCT studying MED was discontinued due to adverse events. Two studies reported MED-induced HS. BTX was overall helpful in HS patients, including in patients without concomitant hyperhidrosis. However, more prospective studies are needed to examine its utility in HS. There is potential harm of MEDs in HS. Most studies examining hyperhidrosis treatments in HS patients are low level of evidence. Larger RCTs should examine the efficacy and tolerability of hyperhidrosis treatments in HS.
“…Two RCTs studied its use in hyperhidrosis, and results were equivocal but promising: one study on 19 patients noted improvement in hyperhidrosis on both the treated and untreated axilla, while another study on 100 patients noted it to be comparable to curettage. 26 There is a paucity of literature on utilization of diode laser in HS. Non-ablative light-based therapies in general have been shown to improve HS lesions.…”
Section: Discussionmentioning
confidence: 99%
“…The role of the diode laser in treatment of hyperhidrosis is not well studied. Two RCTs studied its use in hyperhidrosis, and results were equivocal but promising: one study on 19 patients noted improvement in hyperhidrosis on both the treated and untreated axilla, while another study on 100 patients noted it to be comparable to curettage 26 . There is a paucity of literature on utilization of diode laser in HS.…”
Hyperhidrosis impairs quality of life (QOL) in hidradenitis suppurativa (HS) patients and may exacerbate HS. However, there is limited literature on whether hyperhidrosis treatments improve HS disease. To systematically review literature on efficacy and tolerability of hyperhidrosis treatments in HS patients. In May 2021, MEDLINE and EMBASE databases were systematically searched by two reviewers per PRISMA guidelines for articles on hyperhidrosis and HS. Sixteen articles met inclusion criteria (2 randomized controlled trials [RCTs], one case-control study, three cross-sectional studies, 10 case-studies/ series), encompassing 252 HS patients across studies. They examined botulinum toxin A (BTX-A) (n = 6) and B (BTX-B) (n = 1), suction-curettage (n = 1), diode laser (n = 1), and microwave-based energy device (MED) (n = 3). Overall, BTX treatments improve HS severity, QOL, hyperhidrosis, and were well-tolerated. Suction-curettage did not improve disease. One HS patient tolerated diode laser well, with improvement in sweating and HS. One RCT studying MED was discontinued due to adverse events. Two studies reported MED-induced HS. BTX was overall helpful in HS patients, including in patients without concomitant hyperhidrosis. However, more prospective studies are needed to examine its utility in HS. There is potential harm of MEDs in HS. Most studies examining hyperhidrosis treatments in HS patients are low level of evidence. Larger RCTs should examine the efficacy and tolerability of hyperhidrosis treatments in HS.
“…Propranolol has been also used in the treatment of various rare vascular diseases, including hereditary haemorrhagic telangiectasia, von Hippel–Lindau disease, paraganglioma syndrome, cerebral cavernous malformations, angiosarcoma, and tuberous sclerosis [ 132 ]. Oral propranolol administration seems to be an effective method to minimise the development of sight-threatening choroidal effusion after glaucoma surgery [ 133 ] as well as an effective and safe medication in the treatment of primary hyperhidrosis [ 134 ].…”
Propranolol, a non-cardioselective β1,2 blocker, is most commonly recognised for its application in the therapy of various cardiovascular conditions, such as hypertension, coronary artery disease, and tachyarrhythmias. However, due to its ability to cross the blood–brain barrier and affinity towards multiple macromolecules, not only adrenoreceptors, it has also found application in other fields. For example, it is one of the very few medications successfully applied in the treatment of stage fright. This review focuses on the application of propranolol in the treatment of various types of anxiety and stress, with particular reference to stage fright and post-traumatic stress disorder (PTSD). Both mechanisms of action as well as comparison with other therapies are presented. As those indications for propranolol are, in most countries, considered off-label, this review aims to gather information that can be useful while making a decision about the choice of propranolol as a drug in the treatment of those mental conditions.
“…[36] Lasers Nd:YAG 1064 nm and other lasers show significant reduction in hyperhidrosis when associated with surgical excision of the glands. [37][38][39][40][41][42]…”
Axillary hyperhidrosis results from excessive sweat production in the armpits. It adversely impacts a patient’s quality of life. In this update, we attempt to discuss the basics, pathophysiology, and the management of axillary hyperhidrosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.